根据一项拟议中的新技术，旅客将能够在机场进行检测，以确认他们是否对新冠病毒有足够的免疫力。 <br />
快速检测将通过采集手指血样进行，15分钟内即可得到检测结果。
该检测将确定被检者是否有感染新冠病毒或将病毒传染给他人的风险。
拥有该技术的公司表示，这一检测系统可以加快国际旅行的回归速度，并帮助旅行的人们避免酒店隔离。
该检测技术已向澳大利亚和新西兰政府推介，如果获得批准，会在7月之前推出。
总部位于新西兰的研发公司Orbis Diagnostics和法国跨国技术公司IDEMIA共同开发这一新技术。
IDEMIA大洋洲董事总经理Xavier Assouad表示，正在与澳大利亚各州和领地以及联邦政府的卫生官员进行磋商。
Assouad先生说，“需要经历必要的程序，这是可以理解的。”
他指出，一旦第一代新冠疫苗被广泛接种，免疫筛查技术将成为恢复国际旅行的“关键”。
到目前为止，定量免疫检测仅在医学实验室中可用。
根据拟议的检测模型，在机场一台机器可以同时处理多达30个检测。
该系统将允许各国自行设定与免疫相关的风险容忍度阈值。
它将根据旅行者是否已接种新冠疫苗或之前已感染过新冠病毒来区别登记免疫。
Orbis Diagnostics的首席执行官Brent Ogilvie表示，快速准确的测试结果将决定他们是否可以安全进入目的地国家而无需隔离，不必担心会传染他人的同时也避免自己被感染。
他说，该平台是专门为高容量和非实验室环境（例如机场）设计的。
他说：“检测过程非常快，一旦一个人的免疫力被确定足够好，他们就可以避免隔离，确保不会引发新的疫情。”
免疫筛查平台很可能最早在2021年年中首次引入澳大利亚和新西兰机场，然后在亚太地区进一步广泛应用。
原文链接：
https://www.heraldsun.com.au/cor … db959d2c47be9622f28
Travellers would be able to take a test at the airport to check if they are sufficiently immune to COVID-19, under a proposed new technology.
The rapid testing would be collected through finger prick blood samples, with results returned within 15 minutes.
It would determine if they were at risk of being infected with coronavirus or infecting others.
According to the companies proposing the system, it could speed up a return to international travel and help people avoid hotel quarantine.
The testing technology was being pitched to the Australian and New Zealand governments and if approved could be rolled out by July.
It was under development by New Zealand-based research and development company Orbis Diagnostics and French multinational technology firm IDEMIA.
IDEMIA Oceania managing director Xavier Assouad said talks were underway with health officials in every Australian state and territory, and federally.
Mr Assouad said there was “understandably a process to go through”.
But he said once the first-generation COVID-19 vaccines were widely distributed, immunity screening would become “crucial” to resuming international travel.
Until now, quantitative immunity testing has only been available in medical labs.
Under the proposed model, a single machine at an airport would be able to process up to 30 tests at the same time.
The system would allow countries to set their own thresholds that correlate with their own risk tolerance of immunity.
It will register immunity based on whether the traveller has had the COVID-19 vaccine or been previously infected with the disease.
Orbis Diagnostics chief executive Brent Ogilvie said getting fast and accurate test results would determine whether they were safe to enter their country of destination without quarantining, and without fear of infecting others or being infected themselves.
He said the platform was designed specifically for high-volume and non-laboratory environments, such as airports.
“The process is fast, and once a person’s immunity has been accurately determined, they could bypass quarantine with the assurance there is no substantial risk of causing a fresh outbreak,” he said.
The immunity screening platform was likely to be first introduced to Australian and New Zealand airports as early as mid-2021 before a wider release to the Asia Pacific region.
“唐人街”Fb每日分享澳大利亚精选新闻，让你随时随地知道澳洲最新 @玩乐、@移民、@生活资讯：https://www.fb.com/news.china.com.au/
【欢迎新闻爆料，洽谈合作！】微信订阅帐号：news-china-com-au
